소화기 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gastrointestinal Market size is expected to reach USD 61.19 Billion in 2034 from USD 45.06 Billion (2025) growing at a CAGR of 3.46% during 2026-2034.

The global gastrointestinal market is growing steadily due to the rising prevalence of digestive disorders and increasing awareness about gastrointestinal health. Conditions such as inflammatory bowel disease, acid reflux, and irritable bowel syndrome are becoming more common worldwide, driving demand for effective diagnostic and treatment solutions. The expansion of healthcare services is also supporting market growth.

Advancements in medical technologies, including minimally invasive procedures and advanced diagnostic tools, are improving the management of gastrointestinal conditions. Pharmaceutical companies are investing heavily in research and development to introduce innovative treatments and therapies. Additionally, the increasing adoption of endoscopic procedures is contributing to market expansion.

Looking ahead, the market is expected to grow significantly as healthcare providers continue to focus on early diagnosis and improved treatment options. Increasing healthcare expenditure and the development of advanced gastrointestinal therapies will further drive demand. Growing awareness about digestive health and improved access to healthcare services will also support future market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Branded
• Generics

By Drug Class

• Aminosalicylates
• Digestive enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

By Route of Administration

• Oral
• Injectable
• Others

By Application

• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, AstraZeneca, Salix Pharmaceuticals, Takeda Pharmaceutical Company Limited, Pfizer Inc, Bayer AG, Abbott, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd, Cipla Inc, Gilead Sciences Inc, Biogen, Organon Group of Companies
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROINTESTINAL MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROINTESTINAL MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Aminosalicylates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Digestive enzymes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Proton Pump Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anti-Emetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. H2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Anti-Diarrheal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Biologics/Biosimilar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROINTESTINAL MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROINTESTINAL MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Crohn's disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Ulcerative colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. GERD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. IBS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROINTESTINAL MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GASTROINTESTINAL MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Drug Class
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Application
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Drug Class
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Application
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Drug Class
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Application
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Drug Class
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Application
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Drug Class
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Application
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GASTROINTESTINAL INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie Inc
  • 11.2.2 AstraZeneca
  • 11.2.3 Salix Pharmaceuticals
  • 11.2.4 Takeda Pharmaceutical Company Limited
  • 11.2.5 Pfizer Inc
  • 11.2.6 Bayer AG
  • 11.2.7 Abbott
  • 11.2.8 Janssen Pharmaceuticals NV
  • 11.2.9 Sun Pharmaceutical Industries Ltd
  • 11.2.10 Cipla Inc
  • 11.2.11 Gilead Sciences Inc
  • 11.2.12 Biogen
  • 11.2.13 Organon Group Of Companies